Memic Innovative Surgery, a Tel Aviv, Israel-based medical device company dedicated to transforming robot-assisted surgery with its proprietary technology, closed a $96m Series D financing.
The round was led by Peregrine Ventures and Ceros with participation from OurCrowd and Accelmed.
The company intends to use the funds to commercialize the Hominis® robotic-assisted surgical platform in the U.S. and potentially in other countries around the world and expand marketing and sales efforts outside the U.S. The financing will also support continued research and development efforts including expanding Memic Innovative Surgery’s portfolio of products and manufacturing scaleup, as well as provide customer support and training.
Led by Dvir Cohen, co-founder and CEO, Memic is dedicated to advancing the Hominis system, which received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in February 2021 for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy. The FDA-authorized surgical robotic platform features miniature humanoid-shaped robotic arms that provide human level dexterity, multi-planar flexibility and 360 degrees of articulation. The biomimetic instruments are designed to replicate the motions and capabilities of a surgeon’s arms, with shoulder, elbow and wrist joints. Multiple instruments can be introduced to the body through a single portal and the 360-degree articulation offers obstacle avoidance as well as optimal access and working angles.
The company also has a wholly owned subsidiary in Fort Lauderdale, FL established for global customer services, professional education and sales, marketing and clinical research.